Skip to main content
Erschienen in: Clinical Rheumatology 9/2019

24.04.2019 | Original Article

Malar rash is a predictor of subclinical airway inflammation in patients with systemic lupus erythematosus: a pilot study

verfasst von: Giovanni Damiani, Paolo Daniele Maria Pigatto, Angelo Valerio Marzano, Maurizio Rizzi, Pierachille Santus, Dejan Radovanovic, Ulvi Loite, Lucio Torelli, Stephen Petrou, Piercarlo Sarzi-Puttini, Fabiola Atzeni, Mohammad Adawi, Charlie Bridgewood, Nicola Luigi Bragazzi, Abdulla Watad, Mario Malerba

Erschienen in: Clinical Rheumatology | Ausgabe 9/2019

Einloggen, um Zugang zu erhalten

Abstract

Background

Systemic lupus erythematosus (SLE) is a chronic, auto-immune, multi-organ disease that can affect both the skin and the lungs. Malar rash is a common skin manifestation of SLE and is linked to SLE disease activity, whereas lung involvement is a generally negative prognostic factor for these patients. However, a sensitive and non-invasive screening tool for potential lung involvement in SLE patients is still not available.

Methods

This study aimed to investigate the relationship between malar rash and airway inflammation in adult SLE patients who were not known to have any lung involvement (clinical or radiologic). The study comprised of the measurement of the concentration of NO in exhaled breath or fraction of exhaled nitric oxide (FeNO) and levels were compared between those with and without malar rash. This tool is considered as a sensitive and non-invasive method that is routinely used in patients with asthma or other respiratory diseases to identify airway inflammation.

Results

A total of 125 patients (100 females, 25 males) were enrolled during the study period from January 2011 to December 2014. Patients with malar rash (N = 35) had a significant decrease in serum levels of C4 (p < 0.05) compared to patients without malar rash (N = 90). The mean levels of FeNO in overall patients were 36.44 ± 8.87 ppb. A statistically significant difference in FeNO50 values between patients with malar rash (43.46 ± 6.72 ppb) and without (29.43 ± 3.64 ppb) was found (p < 0.001). FeNO50 values were inversely correlated only with serum C4 (p < 0.01). However, no correlation between FeNO50 values and SLE clinical disease activity scores was found.

Conclusions

The presence of a malar rash may predict sub-clinical airway inflammation in SLE patients. Further prospective studies are needed to confirm the usefulness of FeNO measurements in monitoring SLE-associated airway inflammation.
Literatur
1.
Zurück zum Zitat Arkema EV, Simard JF (2015) Cohort profile: systemic lupus erythematosus in Sweden: the Swedish Lupus Linkage (SLINK) cohort. BMJ Open 14:e008259CrossRef Arkema EV, Simard JF (2015) Cohort profile: systemic lupus erythematosus in Sweden: the Swedish Lupus Linkage (SLINK) cohort. BMJ Open 14:e008259CrossRef
2.
Zurück zum Zitat Bragazzi N-L, McGonagle D, Watad S, et al (2018) Immunogenicity, safety and tolerability of anti-pneumococcal vaccination in systemic lupus erythematosus patients: an evidence-informed and PRISMA compliant systematic review and meta-analysis. Autoimmun Rev 8:73–92 Bragazzi N-L, McGonagle D, Watad S, et al (2018) Immunogenicity, safety and tolerability of anti-pneumococcal vaccination in systemic lupus erythematosus patients: an evidence-informed and PRISMA compliant systematic review and meta-analysis. Autoimmun Rev 8:73–92
3.
4.
Zurück zum Zitat Drucker AM, Su J, Mussani F (2016) Prognostic implications of active discoid lupus erythematosus and malar rash at the time of diagnosis of systemic lupus erythematosus: results from a prospective cohort study. Lupus 25:376–381CrossRefPubMed Drucker AM, Su J, Mussani F (2016) Prognostic implications of active discoid lupus erythematosus and malar rash at the time of diagnosis of systemic lupus erythematosus: results from a prospective cohort study. Lupus 25:376–381CrossRefPubMed
5.
Zurück zum Zitat Hamdani MA, Saud Al-Arfaj AR, Parvez K et al (2015) Pulmonary manifestations of systemic lupus erythematosus patients with and without antiphospholipid syndrome. Pak J Med Sci 31:70–75PubMedPubMedCentral Hamdani MA, Saud Al-Arfaj AR, Parvez K et al (2015) Pulmonary manifestations of systemic lupus erythematosus patients with and without antiphospholipid syndrome. Pak J Med Sci 31:70–75PubMedPubMedCentral
6.
Zurück zum Zitat Mittoo S, Fell CD (2014) Pulmonary manifestations of systemic lupus erythematosus. Semin Respir Crit Care Med 35:249–254CrossRefPubMed Mittoo S, Fell CD (2014) Pulmonary manifestations of systemic lupus erythematosus. Semin Respir Crit Care Med 35:249–254CrossRefPubMed
7.
Zurück zum Zitat Kim MA, Shin YS, Phamle D et al (2014) Adult asthma biomarkers. Curr Opin Allergy Clin Immunol 14:49–54CrossRefPubMed Kim MA, Shin YS, Phamle D et al (2014) Adult asthma biomarkers. Curr Opin Allergy Clin Immunol 14:49–54CrossRefPubMed
8.
9.
Zurück zum Zitat Malerba M, Damiani G, Radaeli A, Ragnoli B, Olivini A, Calzavara-Pinton PG (2015) Narrow-band ultraviolet b phototherapy in psoriasis reduces pro-inflammatory cytokine levels and improves vitiligo and neutrophilic asthma. Br J Dermatol 173:1544–1545CrossRefPubMed Malerba M, Damiani G, Radaeli A, Ragnoli B, Olivini A, Calzavara-Pinton PG (2015) Narrow-band ultraviolet b phototherapy in psoriasis reduces pro-inflammatory cytokine levels and improves vitiligo and neutrophilic asthma. Br J Dermatol 173:1544–1545CrossRefPubMed
10.
Zurück zum Zitat Damiani G, Radaeli A, Olivini A, Calvara-Pinton P, Malerba M (2016) Increased airway inflammation in patients with psoriasis. Br J Dermatol 175:797–799CrossRefPubMed Damiani G, Radaeli A, Olivini A, Calvara-Pinton P, Malerba M (2016) Increased airway inflammation in patients with psoriasis. Br J Dermatol 175:797–799CrossRefPubMed
12.
Zurück zum Zitat Rolla G, Brussino L, Bertero MT, Colagrande P, Converso M, Bucca C, Polizzi S, Caligaris-Cappio F (1997) Increased nitric oxide in exhaled air of patients with systemic lupus erythematosus. J Rheumatol 24:1066–1071PubMed Rolla G, Brussino L, Bertero MT, Colagrande P, Converso M, Bucca C, Polizzi S, Caligaris-Cappio F (1997) Increased nitric oxide in exhaled air of patients with systemic lupus erythematosus. J Rheumatol 24:1066–1071PubMed
13.
Zurück zum Zitat Petri M, Orbai A-M, Alarcón G-S, Gordon C, Merrill JT, Fortin PR, Bruce IN, Isenberg D, Wallace DJ, Nived O, Sturfelt G, Ramsey-Goldman R, Bae SC, Hanly JG, Sánchez-Guerrero J, Clarke A, Aranow C, Manzi S, Urowitz M, Gladman D, Kalunian K, Costner M, Werth VP, Zoma A, Bernatsky S, Ruiz-Irastorza G, Khamashta MA, Jacobsen S, Buyon JP, Maddison P, Dooley MA, van Vollenhoven RF, Ginzler E, Stoll T, Peschken C, Jorizzo JL, Callen JP, Lim SS, Fessler BJ, Inanc M, Kamen DL, Rahman A, Steinsson K, Franks AG Jr, Sigler L, Hameed S, Fang H, Pham N, Brey R, Weisman MH, McGwin G Jr, Magder LS (2012) Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 64(8):2677–2686CrossRefPubMedPubMedCentral Petri M, Orbai A-M, Alarcón G-S, Gordon C, Merrill JT, Fortin PR, Bruce IN, Isenberg D, Wallace DJ, Nived O, Sturfelt G, Ramsey-Goldman R, Bae SC, Hanly JG, Sánchez-Guerrero J, Clarke A, Aranow C, Manzi S, Urowitz M, Gladman D, Kalunian K, Costner M, Werth VP, Zoma A, Bernatsky S, Ruiz-Irastorza G, Khamashta MA, Jacobsen S, Buyon JP, Maddison P, Dooley MA, van Vollenhoven RF, Ginzler E, Stoll T, Peschken C, Jorizzo JL, Callen JP, Lim SS, Fessler BJ, Inanc M, Kamen DL, Rahman A, Steinsson K, Franks AG Jr, Sigler L, Hameed S, Fang H, Pham N, Brey R, Weisman MH, McGwin G Jr, Magder LS (2012) Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 64(8):2677–2686CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Dweik RA, Boggs PB, Erzurum SC, Irvin CG, Leigh MW, Lundberg JO, Olin AC, Plummer AL, Taylor DR, on behalf of the American Thoracic Society Committee on Interpretation of Exhaled Nitric Oxide Levels (Fe) for Clinical Applications (2011) An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med 184:602–615CrossRefPubMedPubMedCentral Dweik RA, Boggs PB, Erzurum SC, Irvin CG, Leigh MW, Lundberg JO, Olin AC, Plummer AL, Taylor DR, on behalf of the American Thoracic Society Committee on Interpretation of Exhaled Nitric Oxide Levels (Fe) for Clinical Applications (2011) An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med 184:602–615CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Malerba M, Damiani G, Carpagnano G et al (2016) Values in Elderly People for Exhaled Nitric Oxide (VEPENO) study. Rejuvenation Res 19:233–238CrossRefPubMed Malerba M, Damiani G, Carpagnano G et al (2016) Values in Elderly People for Exhaled Nitric Oxide (VEPENO) study. Rejuvenation Res 19:233–238CrossRefPubMed
16.
Zurück zum Zitat Santus P, Rizzi M, Radovanovic D, Airoldi A, Cristiano A, Conic R, Petrou S, Pigatto PDM, Bragazzi N, Colombo D, Goldust M, Damiani G (2018) Psoriasis and respiratory comorbidities: the added value of fraction of exhaled nitric oxide as a new method to detect, evaluate, and monitor psoriatic systemic involvement and therapeutic efficacy. Biomed Res Int 2018:3140682. https://doi.org/10.1155/2018/3140682 CrossRefPubMedPubMedCentral Santus P, Rizzi M, Radovanovic D, Airoldi A, Cristiano A, Conic R, Petrou S, Pigatto PDM, Bragazzi N, Colombo D, Goldust M, Damiani G (2018) Psoriasis and respiratory comorbidities: the added value of fraction of exhaled nitric oxide as a new method to detect, evaluate, and monitor psoriatic systemic involvement and therapeutic efficacy. Biomed Res Int 2018:3140682. https://​doi.​org/​10.​1155/​2018/​3140682 CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Alamoudi OS, Attar SM (2015) Pulmonary manifestations in systemic lupus erythematosus: association with disease activity. Respirology 20:474–480CrossRefPubMedPubMedCentral Alamoudi OS, Attar SM (2015) Pulmonary manifestations in systemic lupus erythematosus: association with disease activity. Respirology 20:474–480CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Brunner HI, Holland M, Beresford MW, Ardoin SP, Appenzeller S, Silva CA, Flores F, Goilav B, Wenderfer SE, Levy DM, Ravelli A, Khunchandani R, Avcin T, Klein-Gitelman MS, Feldman BM, Ruperto N, Ying J, the PRCSG and PRINTO Investigators (2018) American College of Rheumatology Provisional Criteria for Global Flares in Childhood-Onset Systemic Lupus Erythematosus. Arthritis Care Res 70:813–822. https://doi.org/10.1002/acr.23557 CrossRef Brunner HI, Holland M, Beresford MW, Ardoin SP, Appenzeller S, Silva CA, Flores F, Goilav B, Wenderfer SE, Levy DM, Ravelli A, Khunchandani R, Avcin T, Klein-Gitelman MS, Feldman BM, Ruperto N, Ying J, the PRCSG and PRINTO Investigators (2018) American College of Rheumatology Provisional Criteria for Global Flares in Childhood-Onset Systemic Lupus Erythematosus. Arthritis Care Res 70:813–822. https://​doi.​org/​10.​1002/​acr.​23557 CrossRef
20.
Zurück zum Zitat Ahmed HH, Taha FM, Darweesh HS, Morsi HM (2014) Association between TNF promoter 2308 G>A and LTA 252 A>G polymorphisms and systemic lupus erythematosus. Mol Biol Rep 41:2029–2036CrossRefPubMed Ahmed HH, Taha FM, Darweesh HS, Morsi HM (2014) Association between TNF promoter 2308 G>A and LTA 252 A>G polymorphisms and systemic lupus erythematosus. Mol Biol Rep 41:2029–2036CrossRefPubMed
21.
Zurück zum Zitat Sanchez E, Nadig A, Richardson BC, Freedman BI, Kaufman KM, Kelly JA, Niewold TB, Kamen DL, Gilkeson GS, Ziegler JT, Langefeld CD, Alarcon GS, Edberg JC, Ramsey-Goldman R, Petri M, Brown EE, Kimberly RP, Reveille JD, Vila LM, Merrill JT, Anaya JM, James JA, Pons-Estel BA, Martin J, Park SY, Bang SY, Bae SC, Moser KL, Vyse TJ, Criswell LA, Gaffney PM, Tsao BP, Jacob CO, Harley JB, Alarcon-Riquelme ME, on behalf of BIOLUPUS and GENLES, Sawalha AH (2011) Phenotypic associations of genetic susceptibility loci in systemic lupus erythematosus. Ann Rheum Dis 70:1752–1757CrossRefPubMed Sanchez E, Nadig A, Richardson BC, Freedman BI, Kaufman KM, Kelly JA, Niewold TB, Kamen DL, Gilkeson GS, Ziegler JT, Langefeld CD, Alarcon GS, Edberg JC, Ramsey-Goldman R, Petri M, Brown EE, Kimberly RP, Reveille JD, Vila LM, Merrill JT, Anaya JM, James JA, Pons-Estel BA, Martin J, Park SY, Bang SY, Bae SC, Moser KL, Vyse TJ, Criswell LA, Gaffney PM, Tsao BP, Jacob CO, Harley JB, Alarcon-Riquelme ME, on behalf of BIOLUPUS and GENLES, Sawalha AH (2011) Phenotypic associations of genetic susceptibility loci in systemic lupus erythematosus. Ann Rheum Dis 70:1752–1757CrossRefPubMed
22.
Zurück zum Zitat Shi ZR, Cao CX, Tan GZ, Wang L (2015) The association of serum anti-ribosomal P antibody with clinical and serological disorders in systemic lupus erythematosus: a systematic review and meta-analysis. Lupus 24:588–596CrossRefPubMed Shi ZR, Cao CX, Tan GZ, Wang L (2015) The association of serum anti-ribosomal P antibody with clinical and serological disorders in systemic lupus erythematosus: a systematic review and meta-analysis. Lupus 24:588–596CrossRefPubMed
23.
Zurück zum Zitat Li J, Leng X, Li Z et al (2014) Chinese SLE treatment and research group registry: III. Association of autoantibodies with clinical manifestations in Chinese patients with systemic lupus erythematosus. J Immunol Res 2014:809389PubMedPubMedCentral Li J, Leng X, Li Z et al (2014) Chinese SLE treatment and research group registry: III. Association of autoantibodies with clinical manifestations in Chinese patients with systemic lupus erythematosus. J Immunol Res 2014:809389PubMedPubMedCentral
24.
Zurück zum Zitat Cervera R, Khamashta MA, Font J et al (1993) Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. The European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore) 72:113–124CrossRef Cervera R, Khamashta MA, Font J et al (1993) Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. The European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore) 72:113–124CrossRef
25.
Zurück zum Zitat Roos AB, Mori M, Grönneberg R et al (2014) Elevated exhaled nitric oxide in allergen-provoked asthma is associated with airway epithelial iNOS. PLoS One 28:e9001 Roos AB, Mori M, Grönneberg R et al (2014) Elevated exhaled nitric oxide in allergen-provoked asthma is associated with airway epithelial iNOS. PLoS One 28:e9001
26.
Zurück zum Zitat Stanga SD, Page SL, Dinakar C (2012) The role of exhaled nitric oxide (FENO) in eosinophilic esophagitis: a pilot study to evaluate the correlation of exhaled nitric oxide and esophageal eosinophils. J Al Clin Immunol 129:AB97 Stanga SD, Page SL, Dinakar C (2012) The role of exhaled nitric oxide (FENO) in eosinophilic esophagitis: a pilot study to evaluate the correlation of exhaled nitric oxide and esophageal eosinophils. J Al Clin Immunol 129:AB97
27.
Zurück zum Zitat Thornadtsson A, Lind A, Weitoft T, Högman M (2018) Altered levels of exhaled nitric oxide in rheumatoid arthritis. Nitric Oxide 76:1–5CrossRefPubMed Thornadtsson A, Lind A, Weitoft T, Högman M (2018) Altered levels of exhaled nitric oxide in rheumatoid arthritis. Nitric Oxide 76:1–5CrossRefPubMed
28.
Zurück zum Zitat Rubinstein E, Rosen RL (2018) Respiratory symptoms associated with eosinophilic esophagitis. Pediatr Pulmonol 53:1587–1591CrossRefPubMed Rubinstein E, Rosen RL (2018) Respiratory symptoms associated with eosinophilic esophagitis. Pediatr Pulmonol 53:1587–1591CrossRefPubMed
29.
Zurück zum Zitat Shaw M, Collins BF, Ho LA, Raghu G (2015) Rheumatoid arthritis-associated lung disease. Eur Respir Rev 24:1–16CrossRefPubMed Shaw M, Collins BF, Ho LA, Raghu G (2015) Rheumatoid arthritis-associated lung disease. Eur Respir Rev 24:1–16CrossRefPubMed
Metadaten
Titel
Malar rash is a predictor of subclinical airway inflammation in patients with systemic lupus erythematosus: a pilot study
verfasst von
Giovanni Damiani
Paolo Daniele Maria Pigatto
Angelo Valerio Marzano
Maurizio Rizzi
Pierachille Santus
Dejan Radovanovic
Ulvi Loite
Lucio Torelli
Stephen Petrou
Piercarlo Sarzi-Puttini
Fabiola Atzeni
Mohammad Adawi
Charlie Bridgewood
Nicola Luigi Bragazzi
Abdulla Watad
Mario Malerba
Publikationsdatum
24.04.2019
Verlag
Springer London
Erschienen in
Clinical Rheumatology / Ausgabe 9/2019
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-019-04536-y

Weitere Artikel der Ausgabe 9/2019

Clinical Rheumatology 9/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.